SMPX gene – Talk Bio

FDA Approves CSL’s Andembry, Directly Competing With Takeda’s Takhzyro in HAE

3 weeks ago talkbio0Tagged Andembry, Angioedemas, Hereditary, Approved, dosing, factor XIIa, garadacimab-gxii, Inhibitor, SMPX gene, Subcutaneous Injections, Takeda, Takhzyro, United States Food and Drug Administration

Andembry; garadacimab-gxii; FDA approval; hereditary angioedema; HAE; CSL; Takhzyro; Takeda; factor XIIa inhibitor; once-monthly dosing; subcutaneous injection

Tourmaline Bio’s Heart Drug Pacibekitug Shows Promise Against Cardiovascular Inflammation, Targets Competition with Novo, CSL

2 months ago talkbio0Tagged Cardiovascular system, heart drug, Inflammation, interleukin-6, Markers (device), Nordisk, pacibekitug, Phase 2 trial, SMPX gene, tourmaline, United States Food and Drug Administration

Tourmaline Bio; heart drug; pacibekitug; cardiovascular inflammation; inflammation markers; Novo Nordisk; CSL; Phase 2 trial; FDA; IL-6

As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay

3 months ago talkbio0Tagged alternatives, Clinical Trials, gene therapy, Hemgenix, HYMPAVZI, Pfizer, SMPX gene

Hemgenix, SMPX gene, Pfizer, gene therapy, alternatives, HYMPAVZI, Clinical Trials

CSL Behring to Close California R&D Site Amid Shift in Gene Therapy Strategy

8 months ago talkbio0Tagged Behring, California, ex vivo, gene therapy, Industry, R&D site closure, SMPX gene, strategic, trends qualifier

CSL Behring, California R&D site closure, ex vivo gene therapy, strategic repositioning, biotech industry trends

CSL Behring Closes California R&D Site, Shifts Operations to Massachusetts Amid Strategic Repositioning

8 months ago talkbio0Tagged Behring, California, ex vivo, gene therapy, Massachusetts relocation, R&D site closure, SMPX gene, strategic

CSL Behring, California R&D site closure, gene therapy, ex vivo work, strategic repositioning, Massachusetts relocation